Apellis Director Mikael Dolsten Exits All Holdings After Biogen’s $41‑Per‑Share Tender Offer

TL;DR: Mikael Dolsten, a director of Apellis Pharmaceuticals, sold all his Apellis shares and options as part of Biogen’s $41‑per‑share tender offer, receiving cash plus a contingent value right that could add up to $4 more per share. After the transaction he holds no remaining stake in the company.

Context Apellis Pharmaceuticals, listed on NASDAQ as APLS, agreed to be acquired by Biogen in a deal announced earlier this year.

Under the merger agreement, each Apellis share tendered to Biogen’s subsidiary would be exchanged for $41 in cash plus one contingent value right (CVR). The CVR entitles the holder to receive up to an additional $4 per share if certain development milestones are met.

The transaction values Apellis at approximately $11.3 billion, reflecting the $41 per share price for roughly 275 million shares outstanding.

Key Facts Mikael Dolsten disposed of 14,312 Apellis common shares and 24,135 stock options in connection with the tender offer and subsequent merger.

The share sale gave him $41 per share in cash and one CVR per share. The options were cancelled and paid out as cash based on the $41 strike price, also with one CVR per option share.

After these dispositions, Dolsten reported holding zero Apellis shares or options.

What It Means The transactions are a direct result of the merger mechanics and do not necessarily reflect Dolsten’s personal outlook on Apellis’s future prospects.

His remaining financial interest now consists solely of the cash already received and any potential CVR payments tied to milestone achievement.

Because the CVR payouts depend on future clinical or regulatory outcomes, the ultimate value of his exit remains uncertain.

Analysts note that such dispositions are routine in mergers and do not convey insider sentiment about the company's standalone value.

Investors will watch for any milestone achievements that could trigger the additional CVR payments and for how the integrated Apellis‑Biogen business performs.